Includes a comparison of anti-CD20 therapies (rituximab, ocrelizumab, ofatumumab), depth and duration of B cell suppression, time to B cell reconstitution, and current data on reduced-dose regimens, extended-interval dosing and personalized dosing.
14 slides
Provides information on SPMS diagnosis, active and progressive sub-phenotypes, time to SPMS in historical and contemporary cohorts, age and EDSS score as predictors of SPMS, and patients’ symptom that may herald the transition to SPMS.
10 slides
Provides information on CD20, binding epitopes of anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, ofatumumab, ublituximab) and the effects of anti-CD20 MAbs in multiple sclerosis. Includes slides explaining antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
12 slides
Summarizes recent data on the UK (B.1.1.7), Brazil (P.1) and South Africa (B.1.351) variants. Also included are the number of variant cases reported in Canada and the U.S. as of March 9, 2021.
9 slides
Updates the February 11 slide deck. Includes data on the immune response to SARS-CoV-2, efficacy data for the Oxford-AstraZeneca vaccine, and updates the vaccine recommendations from the Canadian Network of MS Clinics.
13 slides